Home › Research › Mild cognitive impairment
Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: A large cohort study
Filippos Anagnostakis, Michail Kokkorakis, Christos Asvestis, Ilias Papadimopoulos, Shrihari Nagarajan, Konrad Talbot, Lu Li, Yong Chen et al.. Alzheimer s & Dementia, 2025-09-01
Topic: Risk, prevention and care in population studies
Plain-language summary
During a 7-year median follow-up, type 2 diabetes was associated with the highest risk of all-cause dementia (hazard ratio [HR] 1.18, 95% confidence interval [CI]: 1.06 to 1.31), followed by hypertension and hyperlipidemia. For vascular dementia, type 2 diabetes conferred the greatest risk (HR 1.33, 95% CI: 1.07 to 1.64). Hyperlipidemia was the sole cardiometabolic factor significantly associated with Alzheimer's disease (AD) risk (HR 1.21, 95% CI: 1.11 to 1.32). Hyperlipidemia is primarily associated with AD dementia risk, while type 2 diabetes is the major contributor to vascular dementia and all-cause risk in individuals with MCI. HIGHLIGHTS: Type 2 diabetes, hypertension, and hyperlipidemia are associated with a high risk of developing all-cause dementia in participants already diagnosed with mild cognitive impairment (MCI). Type 2 diabetes was shown to pose a high risk for the progression from MCI to vascular dementia. Hyperlipidemia was associated with Alzheimer's disease progression in individuals with MCI.
What this study adds
Evidence grade: Moderate
In people with mild cognitive impairment, type 2 diabetes carried the highest risk of all-cause dementia and vascular dementia, while hyperlipidemia was the only cardiometabolic factor significantly associated with Alzheimer's disease risk. Reported effect size: HR 1.33; HR 1.21.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Anagnostakis, F., Kokkorakis, M., Asvestis, C., Papadimopoulos, I., Nagarajan, S., Talbot, K., et al. (2025). Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: A large cohort study. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70692
Vancouver
Anagnostakis F, Kokkorakis M, Asvestis C, Papadimopoulos I, Nagarajan S, Talbot K, et al. Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: A large cohort study. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70692. PMID: 40951936.
BibTeX
@article{anagnostakis2025-40951936,
author = {Anagnostakis, Filippos and Kokkorakis, Michail and Asvestis, Christos and Papadimopoulos, Ilias and Nagarajan, Shrihari and Talbot, Konrad and Li, Lu and Chen, Yong and others},
title = {{Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: A large cohort study}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70692},
pmid = {40951936},
url = {https://doi.org/10.1002/alz.70692}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- During a 7-year median follow-up, type 2 diabetes was associated with the highest risk of all-cause dementia (hazard ratio [HR] 1.18, 95% confidence interval [CI]: 1.06 to 1.31), followed by hypertension and hyperlipidemia.
- For vascular dementia, type 2 diabetes conferred the greatest risk (HR 1.33, 95% CI: 1.07 to 1.64).
- Hyperlipidemia was the sole cardiometabolic factor significantly associated with Alzheimer's disease (AD) risk (HR 1.21, 95% CI: 1.11 to 1.32).
- Hyperlipidemia is primarily associated with AD dementia risk, while type 2 diabetes is the major contributor to vascular dementia and all-cause risk in individuals with MCI.
- HIGHLIGHTS: Type 2 diabetes, hypertension, and hyperlipidemia are associated with a high risk of developing all-cause dementia in participants already diagnosed with mild cognitive impairment (MCI).
Why it matters
In people with mild cognitive impairment, type 2 diabetes carried the highest risk of all-cause dementia and vascular dementia, while hyperlipidemia was the only cardiometabolic factor significantly associated with Alzheimer's disease risk. These are observational risk associations and do not test any treatment, cure or prevention.
Study details
- Effect sizeHR 1.33; HR 1.21
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christos A. Davatzikos: h-index 124 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40951936) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Mild cognitive impairment from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.